RESUMO
A lupin seed γ-conglutin-enriched preparation was tested in a glucose overload trial with both murine models and adult healthy volunteers. The results with rats showed a dose-dependent significant decrease of blood glucose concentration, which confirmed previous findings obtained with the purified protein. Moreover, three test-product doses equivalent to 630, 315, and 157.5 mg γ-conglutin, orally administered 30 min before the carbohydrate supply, showed a relevant hypoglycemic effect in human trials. Insulin concentrations were not significantly affected. The general hematic parameters did not change at all. This is the first report on the glucose-lowering effect of lupin γ-conglutin in human subjects.
Assuntos
Glicemia/metabolismo , Hipoglicemiantes/farmacologia , Lupinus/química , Extratos Vegetais/farmacologia , Proteínas de Plantas/farmacologia , Adulto , Animais , Relação Dose-Resposta a Droga , Feminino , Teste de Tolerância a Glucose , Humanos , Masculino , Extratos Vegetais/química , Ratos , Valores de Referência , SementesRESUMO
Saccharomyces cerevisiae is widely used as a probiotic compound. Clinical data suggest that this agent is safe and effective. We report two cases of fungemia caused by S. cerevisiae occurring in immunosuppressed patients treated orally with S. boulardii Molecular typing confirmed clonality in isolate strains from patients and the capsule. Physicians caring for immunosuppressed patients must be aware of this potential serious complication of probiotic use.